Improvements in symptom severity and daily living with safinamide in Parkinson's disease: a phase III, randomized, double-blind, placebo-controlled study

被引：1
|
作者：
Szasz, J. [1 ]
Borgohain, R. [2 ]
Bhatt, M. [3 ]
Rossetti, S. [4 ]
Lucini, V. [4 ]
Anand, R. [5 ]
机构：
[1] Emergency Cty Hosp Targu Mures, Targu Mures, Romania
[2] Nizams Inst Med Sci, Hyderabad, India
[3] Kokilaben Dhirubhai Ambani Hosp & Med Res Inst, Mumbai, Maharashtra, India
[4] Newron Pharmaceut SpA, Bresso, Italy
[5] APC AG, St Moritz, Switzerland
来源：
PARKINSONISM & RELATED DISORDERS | 2009年 / 15卷
关键词：
D O I：
10.1016/S1353-8020(09)70459-6
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P2.108
引用
收藏
页码：S118 / S118
页数：1
相关论文
共 50 条
  • [1] Safinamide as an adjunct to levodopa significantly improved motor fluctuations in Parkinson's disease: a phase III, randomized, double-blind, placebo-controlled study
    Borgohain, R.
    Szasz, J.
    Bhatt, M.
    Rossetti, S.
    Lucini, V.
    Anand, R.
    PARKINSONISM & RELATED DISORDERS, 2009, 15 : S115 - S115
  • [2] Liraglutide once daily versus placebo in Parkinson's disease: a randomized, double-blind, placebo-controlled trial
    Wu, T.
    Bresee, C.
    Wertheimer, J.
    Hogg, E.
    Malatt, C.
    Tan, E.
    Pomeroy, H.
    Obialisi, G.
    Tagliati, M.
    MOVEMENT DISORDERS, 2022, 37 : S359 - S360
  • [3] A Randomized, Double-Blind, Placebo-Controlled Trial of Safinamide as Add-on Therapy in Early Parkinson's Disease Patients
    Stocchi, Fabrizio
    Borgohain, Rupam
    Onofrj, Marco
    Schapira, Anthony H. V.
    Bhatt, Mohit
    Lucini, Valentina
    Giuliani, Rodolfo
    Anand, Ravi
    MOVEMENT DISORDERS, 2012, 27 (01) : 106 - 112
  • [4] Opicapone EPSILON study in early Parkinson's: design of a phase III, double-blind, randomized, placebo-controlled study
    Ferreira, J.
    Poewe, W.
    Rascol, O.
    Stocchi, F.
    Antonini, A.
    Moreira, J.
    Rocha, J.
    Soares-da-Silva, P.
    EUROPEAN JOURNAL OF NEUROLOGY, 2021, 28 : 719 - 719
  • [5] A Randomized Double-Blind Placebo-Controlled Phase III Trial of Selegiline Monotherapy for Early Parkinson Disease
    Mizuno, Yoshikuni
    Hattori, Nobutaka
    Kondo, Tomoyoshi
    Nomoto, Masahiro
    Origasa, Hideki
    Takahashi, Ryosuke
    Yamamoto, Mitsutoshi
    Yanagisawa, Nobuo
    CLINICAL NEUROPHARMACOLOGY, 2017, 40 (05) : 201 - 207
  • [6] Efficacy and safety of safinamide as an add-on therapy to L-DOPA for patients with Parkinson's disease: A randomized, double-blind, placebo-controlled, phase II/III study
    Hattori, Nobutaka
    Tsuboi, Yoshio
    Yamamoto, Akihiko
    Sasagawa, Yuji
    Nomoto, Masahiro
    PARKINSONISM & RELATED DISORDERS, 2020, 75 : 17 - 23
  • [7] A Randomized, Double-Blind, Placebo-Controlled Trial of Camicinal in Parkinson's Disease
    Marrinan, Sarah L.
    Otiker, Tal
    Vasist, Lakshmi S.
    Gibson, Rachel A.
    Sarai, Bhopinder K.
    Barton, Matthew E.
    Richards, Duncan B.
    Hellstrom, Per M.
    Nyholm, Dag
    Dukes, George E.
    Burn, David J.
    MOVEMENT DISORDERS, 2018, 33 (02) : 329 - 332
  • [8] Rivastigmine in dementia associated with Parkinson's disease: A randomized, double-blind, placebo-controlled study
    Emre, M.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2006, 248 (1-2) : 298 - 298
  • [9] Mucuna pruriens in parkinson's disease: a double-blind, randomized, placebo-controlled, crossover study
    Cilia, R.
    Laguna, J.
    Cassani, E.
    Cereda, E.
    Pezzoli, G.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2015, 357 : E262 - E263
  • [10] Helicobacter pylori eradication in Parkinson's disease: A double-blind randomized placebo-controlled study
    Tan, A. H.
    Lim, S. Y.
    Mahadeva, S.
    Loke, M. F.
    Vadivelu, J. S.
    Marras, C.
    Fox, H.
    Lang, A. E.
    MOVEMENT DISORDERS, 2020, 35 : S422 - S425
12345